What is HC Wainwright’s Forecast for CGTX FY2026 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Stock analysts at HC Wainwright boosted their FY2026 EPS estimates for Cognition Therapeutics in a research report issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.18) for the year, up from their previous forecast of ($0.20). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.04) EPS, Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.18) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last announced its earnings results on Thursday, November 5th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03.

Several other equities analysts have also recently issued reports on the company. Wall Street Zen cut Cognition Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, September 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cognition Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $3.33.

Cognition Therapeutics Stock Performance

CGTX opened at $0.67 on Wednesday. Cognition Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.81. The business has a 50 day moving average price of $0.87 and a two-hundred day moving average price of $1.04.

Hedge Funds Weigh In On Cognition Therapeutics

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Cognition Therapeutics in the 2nd quarter worth approximately $1,451,000. Tocqueville Asset Management L.P. acquired a new position in Cognition Therapeutics in the second quarter worth approximately $369,000. Renaissance Technologies LLC increased its holdings in shares of Cognition Therapeutics by 15.2% in the first quarter. Renaissance Technologies LLC now owns 1,117,136 shares of the company’s stock valued at $848,000 after buying an additional 147,623 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Cognition Therapeutics in the second quarter valued at $165,000. Finally, Sigma Planning Corp lifted its position in shares of Cognition Therapeutics by 56.3% during the 1st quarter. Sigma Planning Corp now owns 337,765 shares of the company’s stock valued at $257,000 after acquiring an additional 121,600 shares during the last quarter. Institutional investors and hedge funds own 43.35% of the company’s stock.

More Cognition Therapeutics News

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings forecasts, narrowing its projected annual loss to $0.18 per share from $0.20 and $0.19, respectively. It also improved several quarterly estimates to a loss of $0.04 per share from $0.05 and maintained its Buy rating.
• Positive Sentiment: Cognition Therapeutics was upgraded to Zacks Rank #2 (Buy), reflecting improving earnings expectations and potentially bolstering near-term sentiment. Article: What Makes Cognition Therapeutics (CGTX) a New Buy Stock
• Neutral Sentiment: CEO Lisa Ricciardi plans to attend the Jefferies Global Healthcare Conference on November 16–19 and discuss the company’s recent FDA meeting on endpoints for a planned Phase 3 zervimesine study in dementia with Lewy bodies. No new FDA decision or trial outcome was announced. Article: Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
• Neutral Sentiment: A short-interest report described a large increase but listed total short interest as zero shares, making the figures inconsistent and difficult to interpret.
• Negative Sentiment: At the provided $0.67 reference price, CGTX remains below its 50-day ($0.87) and 200-day ($1.04) moving averages, indicating a weaker recent technical trend despite the positive analyst revisions.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration. Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.